Efficacy of COVID-19 vaccines

Saadh, Mohamed J.; Jaber, Saif Aldeen

doi:10.1016/j.micpath.2022.105729

Cited by 14 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 30 ] A study published in the China CDC Weekly revealed that the mortality rate for people with cardiovascular disease was 10.5% as against 0.9% for those without comorbidities. [ 31 ] However, Saadh and Jaber[ 19 ] studied the relative effectiveness of 3 vaccines including BNT162b2, BBIBP-CorV, and ChAdOx1 nCoV-19 vaccines for 6,132 adults with diabetes, and chronic cardiovascular and respiratory conditions; the death rate in patients was 7.9%–25.1% after the first dose, with a reduction 0.175% (~0.2%) to 2.7% after the second dose. These show that the vaccines reduced mortality even in people with preexisting conditions.…”

Section: Discussionmentioning

confidence: 99%

“…The hospitalization rate after vaccination was reported to be 0.002% (<0.1%) after 2 doses of BNT162b2, BBIBP-CorV, or ChAdOx1 nCoV-19 vaccines. [ 7 ] For people living with diabetes, and chronic cardiovascular and respiratory conditions, Saadh and Jaber[ 19 ] showed that hospitalizations also reduced with a range of 7.9%–25.1% with one dose to 6.0%–7.9% after a second dose of BNT162b2, BBIBP-CorV, and ChAdOx1 nCoV-19 vaccines after two doses. In addition, they also showed that infections without the need for hospitalization increased between 0.7% AND 10.6% after one dose of vaccine to 6.0% to 25.1% after two doses.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy, Safety, and Public Attitude toward COVID-19 Vaccines: A Systematic Review

Josiah,

Uzor,

Duncan

et al. 2023

Annals of African Medicine

View full text Add to dashboard Cite

Background: This paper reviews some of the literature on the safety and efficacy of different COVID-19 vaccines, the attitudes, and perceptions of people towards the vaccines, and the factor underlying such perceptions and behavior. Methods: Two major databases (PubMed and Epistemonikos) were checked using search expansion mechanisms and several search strings. After the title, abstract, and full-text analysis, 19 studies were selected for review. Results: The seven different vaccines studied all have supporting data on their efficacy in the reduction of COVID-19 cases, prevention of hospitalization after infection, and reduction in the mortality rate of COVID-19 patients. There was high hesitancy about the COVID-19 vaccine and the perceived efficacy and safety of the vaccines are less than recorded in clinical data. Distrust of the vaccines, their manufacturers and different institutions and governments, personal beliefs and feelings, age, gender, education, and socioeconomic status were identified factors affecting behaviors towards the COVID-19 vaccines. Conclusion: Several articles support the efficacy of COVID-19 vaccines, but general awareness and conception about them vary, including hesitancy, distrust, and some acceptance. Many factors affected the perception and attitude of people toward these vaccines. More clinical data on the efficacy and safety of COVID-19 vaccines should be generated to help boost confidence among users.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy, Safety, and Public Attitude toward COVID-19 Vaccines: A Systematic Review

Josiah,

Uzor,

Duncan

et al. 2023

Annals of African Medicine

View full text Add to dashboard Cite

show abstract

“…Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection provide good protection against severe COVID-19 for most people [ 1 ]. However, several groups of patients remain at risk for severe disease despite repeated vaccinations, including patients on certain immunosuppressive medications [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy

Feuth,

Nieminen,

Palomäki

et al. 2024

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Purpose In clinical practice, we observed an apparent overrepresentation of COVID-19 patients on anti-CD20 monoclonal antibody therapy. The aim of this study was to characterize the clinical picture of COVID-19 in these patients. Methods All adult patients from Turku University Hospital, Turku, Finland, with COVID-19 diagnosis and/or positive SARS-CoV-2 PCR test result up to March 2023, and with anti-CD20 therapy within 12 months before COVID-19 were included. Data was retrospectively obtained from electronic patient records. Results Ninety-eight patients were identified. 44/93 patients (47.3%) were hospitalized due to COVID-19. Patients with demyelinating disorder (n = 20) were youngest (median age 36.5 years, interquartile range 33–45 years), had less comorbidities, and were least likely to be hospitalized (2/20; 10.0%) or die (n = 0). COVID-19 mortality was 13.3% in the whole group, with age and male sex as independent risk factors. Persistent symptoms were documented in 33/94 patients (35.1%) alive by day 30, in 21/89 patients (23.6%) after 60 days, and in 15/85 after 90 days (17.6%), mostly in patients with haematological malignancy or connective tissue disease. Prolonged symptoms after 60 days predisposed to persistent radiological findings (odds ratio 64.0; 95% confidence interval 6.3–711; p < 0.0001) and persistently positive PCR (odds ratio 45.5, 95% confidence interval 4.0–535; p < 0.0001). Several patients displayed rapid response to late antiviral therapy. Conclusion Anti-CD20 monoclonal antibody therapy is associated with high COVID-19 mortality and with a phenotype consistent with prolonged viral pneumonia. Our study provides rationale for retesting of immunocompromised patients with prolonged COVID-19 symptoms and considering antiviral therapy.

show abstract

“…A study showed that the mean percentage of death with one dose was 11.55% compared to 4.31% after the second dose of any type of approved vaccine. 6 Globally, it has been estimated that about eight billion doses of the COVID-19 vaccine have been distributed to reduce the rate of COVID-19. 7 Comprehensively, the COVID-19 vaccination saved approximately 20 million lives during its first year of distribution.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 in the Arab countries: Three-year review

Alwahaibi,

Al Maskari,

Al-Jaaidi

et al. 2024

F1000Res

View full text Add to dashboard Cite

Background Twenty-two Arab countries share a common language, history, and culture. Nevertheless, governmental policies, healthcare systems, and resources differ from one Arab country to another. We have been following Coronavirus (COVID-19) from the beginning in each Arab country. In the present study, we aimed to assess the prevalence of COVID-19 in the Arab world and to compare these findings with other significantly affected countries. Methods Websites of the World Health Organization, World COVID-vaccinations tracker, Worldometer, and Ministries of Health were used to extract COVID-19 data in all Arab countries between the period January 2020 to December 2022. Results All Arab countries had 14,218,042 total confirmed COVID-19 cases, 13,384,924 total recovered cases and 173,544 total related deaths. The trend demonstrated that the third quarter of 2021 recorded the highest death toll and the first quarter of 2022 recorded the highest number of confirmed and recovered cases. Compared to the top 15 affected countries, the Arab world ranked last as it had the lowest overall incidence per million population (PMP) of 31,609. The data on total deaths PMP showed that India had the lowest number of deaths with only 377 cases followed by the Arab world with 386 cases. Conclusions Although the number of confirmed, death, and subsequently recovered cases of COVID-19 have greatly reduced in the last quarter of 2022 in most Arab countries, many Arab countries still need to re-campaign about COVID-19 vaccines and raise awareness programs about boosters. COVID-19 has had a relatively smaller impact on Arab countries than on other countries that have been significantly affected.

show abstract

Efficacy of COVID-19 vaccines

Cited by 14 publications

References 21 publications

Efficacy, Safety, and Public Attitude toward COVID-19 Vaccines: A Systematic Review

Efficacy, Safety, and Public Attitude toward COVID-19 Vaccines: A Systematic Review

Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy

COVID-19 in the Arab countries: Three-year review

Contact Info

Product

Resources

About